939 Stock Overview
Treatment.Com International Inc. provides personalized health care information services in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Treatment.com AI Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.40 |
| 52 Week High | CA$0.75 |
| 52 Week Low | CA$0.23 |
| Beta | -0.58 |
| 1 Month Change | 11.86% |
| 3 Month Change | -20.80% |
| 1 Year Change | 58.40% |
| 3 Year Change | -94.76% |
| 5 Year Change | n/a |
| Change since IPO | -98.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| 939 | DE Healthcare Services | DE Market | |
|---|---|---|---|
| 7D | 7.6% | 16.1% | 1.1% |
| 1Y | 58.4% | -16.6% | 10.3% |
Return vs Industry: 939 exceeded the German Healthcare Services industry which returned -15.6% over the past year.
Return vs Market: 939 exceeded the German Market which returned 9.6% over the past year.
Price Volatility
| 939 volatility | |
|---|---|
| 939 Average Weekly Movement | 12.5% |
| Healthcare Services Industry Average Movement | 6.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 939's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 939's weekly volatility has decreased from 20% to 12% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Essam Hamza | www.treatment.com |
Treatment Com International Inc. provides personalized health care information services in Canada. The company develops a mobile application for symptom assessment of users to address their health concerns, problems, and ongoing wellness management.
Treatment.com AI Inc. Fundamentals Summary
| 939 fundamental statistics | |
|---|---|
| Market cap | €20.78m |
| Earnings (TTM) | -€1.35m |
| Revenue (TTM) | €25.67k |
809.3x
P/S Ratio-15.4x
P/E RatioIs 939 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 939 income statement (TTM) | |
|---|---|
| Revenue | CA$38.14k |
| Cost of Revenue | CA$13.95k |
| Gross Profit | CA$24.19k |
| Other Expenses | CA$2.03m |
| Earnings | -CA$2.01m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.041 |
| Gross Margin | 63.43% |
| Net Profit Margin | -5,268.63% |
| Debt/Equity Ratio | -91.6% |
How did 939 perform over the long term?
See historical performance and comparison